Merck & Co. MRK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $65.77B+2.9% | $65.01B+1.3% | $64.24B+1.7% | $63.62B+1.8% | $63.92B+4.1% | ||
| $17.16B+13.8% | $16.38B+7.8% | $14.66B-4.0% | $14.88B-3.7% | $15.07B-4.2% | ||
| $48.61B-0.5% | $48.63B-0.7% | $49.58B+3.5% | $48.73B+3.6% | $48.85B+7.0% | ||
| 73.9%-2.5pp | 74.8%-1.5pp | 77.2%+1.4pp | 76.6%+1.3pp | 76.4%+2.1pp | ||
| $24.76B+40.9% | $15.79B-12.0% | $16.49B-28.3% | $18.12B-11.3% | $17.57B-41.9% | ||
| $10.88B-0.1% | $10.73B-0.8% | $10.7B-0.5% | $10.8B+2.4% | $10.89B+3.6% | ||
| $11.63B-42.3% | $21.07B+5.7% | $21.82B— | $19.16B— | $20.17B— | ||
| $2.7B-0.8% | $2.81B+0.1% | $2.77B— | $2.74B— | $2.72B— | ||
| $8.94B-48.7% | $18.25B+6.6% | $19.03B— | $16.41B— | $17.43B— | ||
| 13.6%-13.7pp | 28.1%+1.4pp | 29.6%— | 25.8%— | 27.3%— | ||
| $3.56-48.2% | $7.29+8.3% | $7.57— | $6.49— | $6.87— | ||
| $14.75B-33.7% | $24.11B+9.4% | $23.89B— | $21.26B— | $22.26B— | ||
| 22.4%-12.4pp | 37.1%+2.7pp | 37.2%— | 33.4%— | 34.8%— | ||
| $11.63B-42.3% | $21.07B+5.7% | $21.82B— | $19.16B— | $20.17B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Merck & Co.'s revenue?
- Merck & Co. (MRK) generated $65.8B in revenue over the trailing twelve months, up 2.9% year over year.
- Is Merck & Co. profitable?
- Merck & Co. reported $8.9B in net income over the trailing twelve months, a 13.6% net margin.
- What is Merck & Co.'s earnings per share?
- Merck & Co.'s diluted EPS over the trailing twelve months is $3.56.
- Where does Merck & Co.'s income statement data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
